Here, we report a case of chronic granulomatous tubulo-interstitial nephritis related to atazanavir crystals in a HIV type-1-infected patient. Renal function in this patient was partially recovered after atazanavir withdrawal and steroid therapy. Many reports have described atazanavir-associated urolithiasis, but this is the first case that describes chronic granulomatous nephropathy.
Ritonavir-boosted atazanavir is widely prescribed for the treatment of HIV type-1 (HIV-1) infection as part of first-line combination antiretroviral therapy (cART). Many reports have described atazanavir-associated urolithiasis [1, 2, 3] . One report referred to an acute interstitial nephritis related to an atazanavir hypersensitivity reaction [4] and one to an acute interstitial nephritis related to atazanavir crystallization [5] . We report a patient in whom chronic interstitial nephropathy associated with atazanavir crystals occurred.
Case report
The patient was a 60-year-old man of North African origin diagnosed with HIV-1 infection on February 2004. He had no coinfections. CD4 + T-cell count was 62 cells/ml and HIV-1 RNA was >100,000 copies/ml. cART was started on March 2004 with lamivudine, didanosine and lopinavir/ritonavir. Boosted lopinavir was replaced by boosted atazanavir (300/100 mg) because of hypertriglyceridaemia on May 2005. On February 2006, didanosine was replaced by zidovudine to prevent neurological toxicity. Zidovudine was later switched to abacavir in October 2006 on account of mild anaemia and leukopaenia. Of note, HIV-1 infection was well-controlled during the 4 years following cART initiation as CD4 + T-cell count increased to 500 cells/ ml and viral load was controlled to <50 copies/ml until Figure 1A) . Intratubular crystalline precipitation, underlined by a granulomatous reaction, was also noted ( Figure 1B ). This granulomatous peritubular inflammation was never associated with caseous necrosis and preferentially located to the medulla area. No viral inclusion was detected and Ziehl-Neelsen staining was negative. Nine glomeruli were obsolete and the remaining eight were unremarkable. Finally, immunofluorescence analysis was negative.
Polarized light microscopy analysis of urine crystals showed exclusively atazanavir crystals (28. 4 
Discussion
Renal failure as a side effect of antiretroviral therapy has been described in the literature, but few cases have been associated with atazanavir. Nevertheless, Kirk et al. [6 ] recently found that atazanavir therapy is independently associated with a significantly increased rate of chronic kidney disease with an adjusted incidence rate ratio of 1.21 per year (95% confidence interval 1.09-1.34; P=0.0003). Kirk et al. [6] assessed the possibility of crystalluria, crystal nephropathy and nephrolithiasis to explain this. Obstructive urolithiasis is well-known, with an estimated prevalence of 0.97% [2] . Chan-Tack et al. [3] reported 30 cases of nephrolithiasis in HIV-infected patients taking an atazanavirbased regimen, among whom 12 cases had confirmed atazanavir lithiasis. Although interstitial nephropathies affect up to 13% of HIV-infected patients, atazanavirinduced interstitial nephropathies remain rare [4, 5, 7] . Kidney function normalized after both atazanavir and tenofovir withdrawal [7] . To date, only three cases of interstitial nephropathies have been described with the administration of atazanavir without a concomitant nephrotoxic drug [4, 5, 8] . Brewster and Perazella [4] reported a case of acute tubulo-interstitial nephritis, without crystal deposit, occurring 4 weeks after atazanavir was started. Renal function recovered after the discontinuation of atazanavir therapy and the speculated underlying mechanism was hypersensitivity-type reaction. In a retrospective study of 30 renal biopsies from HIV-infected patients, all three patients treated with a combination of atazanavir and tenofovir had an acute interstitial nephritis, occurring between 6 and 16 weeks after starting ritonavir-boosted atazanavir [7] . No crystals were found [7] . Conversely, Izzedine et al. [5] published a very similar case to that of our patient, describing intratubular atazanavir crystals that responded to steroid therapy. In this case, plasma atazanavir concentration was fourfold higher than the expected concentration and urinary pH was alkaline. This patient also had a liver disease. In contrast to that previous case, our patient did not present overdosage of plasma atazanavir concentration, urinary pH was acid and he had no liver disease. Pharmacodynamic studies have shown that atazanavir is metabolized and excreted mainly through the liver, with 7% of unchanged drug recovered in the urine and that its solubility increases with urine acidity (with maximal solubility of 1.9 at 24 ±3°C) [9] . The only risk factor that could be assessed in our case is hypocitraturia in comparison with uric acid and calcium oxalate lithiasis.
In conclusion, this case illustrates the hypothesis of atazanavir crystal nephropathy to explain its association with a significantly increased rate of chronic kidney disease, although it seems to be a rare clinical entity. It has not been previously described with a multinucleated giant cells reaction. We believe that clinicians should be aware of the possibility of developing crystal-associated nephropathy.
